Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy.

Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy.
复制标题

人源化免疫系统小鼠模型构建策略及肿瘤免疫检查点抑制剂治疗评价。

DOI:
10.3389/fonc.2021.673199
复制
发表时间:
2021
影响因子:
4.7
通讯作者:
Shi C
Shi C
中科院分区:
医学3区
文献类型:
--
作者:
Guo W;Zhang C;Qiao T;Zhao J;Shi C

文献摘要

参考文献

被引文献

相似文献

免疫疗法已被用作各种晚期肿瘤的一线治疗,使癌症治疗取得了显着进展。尽管如此,只有少数患者可以从免疫检查点抑制剂单药治疗中获益。为了提高免疫治疗的效果,在完整的人类肿瘤免疫微环境的背景下,使用具有人类免疫系统(HIS)且携带人类肿瘤的小鼠来研究联合治疗的潜在机制。在此,我们总结并讨论了HIS小鼠模型在肿瘤免疫治疗中的开发和使用策略。最重要的是,本文提出了一种基于肿瘤浸润淋巴细胞和PD-L1表达的HIS小鼠肿瘤识别和分类的方法,并根据这种分类,我们提出了不同的联合治疗策略,可用于增强免疫治疗的效果。因此,我们为HIS小鼠模型的肿瘤免疫治疗提供了有效的实验方案。
Immunotherapy has been used as a first-line treatment for a variety of advanced tumors, allowing remarkable progress to be made in cancer treatment. Nonetheless, only a small number of patients can benefit from immune checkpoint inhibitor monotherapy. To improve the effect of immunotherapy, the underlying mechanism of combination therapy was investigated in the context of an intact human tumor immune microenvironment using mice with a human immune system (HIS) bearing human tumors. Herein, we summarize and discuss strategies for the development and use of HIS mice models in tumor immunotherapies. Most importantly, this review proposes a method of t11umor identification and classification in HIS mice based on the tumor-infiltrating lymphocytes and PD-L1 expression, and according to this classification, we propose different combination treatment strategies that can be utilized to enhance the effect of immunotherapy. Thus, we provide effective experimental schemes for tumor immunotherapy in HIS mice models.
DOI: 10.1186/s40425-014-0043-z
发表时间: 2015
影响因子: 10.9
作者:
Jing W;Gershan JA;Weber J;Tlomak D;McOlash L;Sabatos-Peyton C;Johnson BD
通讯作者: Johnson BD
DOI: 10.1158/2326-6066.cir-14-0076
发表时间: 2014-11
影响因子: 10.1
作者:
Farsaci B;Donahue RN;Coplin MA;Grenga I;Lepone LM;Molinolo AA;Hodge JW
通讯作者: Hodge JW
DOI: 10.3389/fimmu.2020.598877
发表时间: 2020
影响因子: 7.3
作者:
Hack SP;Zhu AX;Wang Y
通讯作者: Wang Y
DOI: 10.1080/2162402x.2019.1596005
发表时间: 2019-04-07
期刊: ONCOIMMUNOLOGY
影响因子: 7.2
作者:
Burlion, Aude;Ramos, Rodrigo N.;Marodon, Gilles
通讯作者: Marodon, Gilles
DOI: 10.1016/j.jtho.2019.07.001
发表时间: 2019-10-01
影响因子: 20.4
作者:
Carlos Benitez, Jose;Mezquita, Laura;Besse, Benjamin
通讯作者: Besse, Benjamin